ARKG
ARK Genomic Revolution ETF
📎 Investment Objective
The ARK Genomic Revolution ETF (ARKG) seeks to provide investment results that closely correspond to the performance of the ARK Genomic Revolution Index, which is designed to track the performance of companies that are expected to benefit from the development of genomic and genetic therapy technologies.
Overview
ETF tracking ARK Genomic Revolution ETF
Performance
Price Chart
Investment Summary
📎 Investment Objective
The ARK Genomic Revolution ETF (ARKG) seeks to provide investment results that closely correspond to the performance of the ARK Genomic Revolution Index, which is designed to track the performance of companies that are expected to benefit from the development of genomic and genetic therapy technologies.
🎯 Investment Strategy
The ETF invests primarily in domestic and foreign equity securities of companies that are relevant to the fund's investment theme of the genomic revolution. This includes companies involved in areas such as gene editing, genetic testing, and biotechnology.
✨ Key Features
- Focuses on companies at the forefront of the genomic revolution and genetic therapy technologies
- Diversified portfolio across multiple sub-sectors of the healthcare and biotechnology industries
- Actively managed fund that aims to identify innovative companies with high growth potential
- Relatively high expense ratio compared to broad market index funds
⚠️ Primary Risks
- Significant exposure to the volatile biotechnology and healthcare sectors
- Potential for higher risk and volatility compared to the broader market
- Concentration risk as the fund is focused on a specific investment theme
- Reliance on the fund manager's ability to identify and invest in promising companies
👤 Best For
The ARK Genomic Revolution ETF may be suitable for investors with a long-term investment horizon, a high risk tolerance, and an interest in the potential of genomic and genetic therapy technologies. It is best suited for investors seeking exposure to the growth potential of the healthcare and biotechnology sectors.